Study: NCT01932177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.